Zosano Pharma Corp

ZSANCIK 0001587221 · Every Form 4 filed by insiders at this issuer. See financials →

Annual report (10-K)

Latest 10-K/A filed Apr 29, 2022. Sentiment + YoY language diff vs prior year. Read sections →

Signal:NeutralFull-doc fallback

Full filing:tone 0.0006

Sentiment via Loughran-McDonald lexicon · YoY diff via Jaccard similarity + paragraph set difference.

YoY shift: Unscored

Year-over-year tone shift - average net-tone change across Risk Factors and MD&A vs the prior 10-K.

Why YoY instead of absolute: the LM lexicon has ~6.6× more negative words than positive (legal/risk-disclosure language is heavy on hedging), so every 10-K reads bearish on raw tone. Year-over-year change strips that bias and surfaces the actual shift in management's framing.

Per-snippet highlights

Sentence-level sentiment highlighting with category and subcategory filters is coming once the snippet-scoring pipeline lands. For now, dig into the actual section text on the Sections tab.

Top insiders

Most active reporters at Zosano Pharma Corp

Name	Roles	Filings
Lo Steven	OfficerDirector	2
Matthews Christine	Officer	2
Kellerman Donald J	Officer	1

Showing 1-3 of 3

Per pagePage 1 of 1

All filings

5 Form 4 / 4-A filings, newest first

Filed	Insider	Top transaction	Shares	Price	Value
Jun 7, 2022	Lo Steven Chief Executive Officer · Director	SSale	442	$0.71	$314
Jun 7, 2022	Matthews Christine Chief Financial Officer	SSale	82	$0.71	$58
Apr 1, 2022	Lo Steven Chief Executive Officer · Director	SSale	23,633	$0.2101	$4,965
Apr 1, 2022	Kellerman Donald J VP, Clinical Dev & Med Affairs	SSale	4,006	$0.2101	$842
Apr 1, 2022	Matthews Christine Chief Financial Officer	SSale	8,116	$0.2101	$1,705

Showing 1-5 of 5